HCR MANORCARE
8442 SETTLERS PSGE
April 15, 2008
The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).